Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study

MLA

Sophie de Guibert, et al. “Clinical Activity of Abemaciclib in Patients with Relapsed or Refractory Mantle Cell Lymphoma - a Phase II Study.” Haematologica, vol. 106, May 2020, pp. 859–62. EBSCOhost, https://doi.org/10.3324/haematol.2019.224535.

APA

Sophie de Guibert, P. Kellie Turner, Kamal Bouabdallah, Catherine Thieblemont, Florian Zettl, Siva Rama Prasad Kambhampati, Franck Morschhauser, Li Li, Sean Buchanan, Stephan Stilgenbauer, Lily Q. Li, Susana Barriga, Lawrence M. Gelbert, Martin Wilhelm, Georg Hess, & Melissa M. Bear. (2020). Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study. Haematologica, 106, 859–862. https://doi.org/10.3324/haematol.2019.224535

Chicago

Sophie de Guibert, P. Kellie Turner, Kamal Bouabdallah, Catherine Thieblemont, Florian Zettl, Siva Rama Prasad Kambhampati, Franck Morschhauser, et al. 2020. “Clinical Activity of Abemaciclib in Patients with Relapsed or Refractory Mantle Cell Lymphoma - a Phase II Study.” Haematologica 106 (May): 859–62. doi:10.3324/haematol.2019.224535.